2024Nature communications15 (1) : 1173
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
Sake S, Zhang X, Rajak M, Urbanek-Quaing M, Carpentier A, Gunesch A, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee A, Johnson K, Morwood K, Rox K, Elgaher W, Huang J, Wetzke M, Hansen G, Fischer N, Eléouët J, Rameix-Welti M, Hirsch A, Herold E, Empting M, Lauber C, Schulz T, Krey T, Haid S, Pietschmann T
2022Antimicrobial agents and chemotherapy66 (12) : e0103222
Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
Sake S, Kosch C, Blockus S, Haid S, Gunesch A, Zhang X, Friesland M, Trummer S, Grethe C, Kühnel A, Rückert J, Duprex W, Huang J, Rameix-Welti M, Empting M, Fischer N, Hirsch A, Schulz T, Pietschmann T
2015Journal of virology90 (6) : 3065-73
Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System
Haid S, Grethe C, Bankwitz D, Grunwald T, Pietschmann T
2012Gastroenterology143 (1) : 213-22.e5
A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes
Haid S, Novodomská A, Gentzsch J, Grethe C, Geuenich S, Bankwitz D, Chhatwal P, Jannack B, Hennebelle T, Bailleul F, Keppler O, Poenisch M, Bartenschlager R, Hernandez C, Lemasson M, Rosenberg A, Wong-Staal F, Davioud-Charvet E, Pietschmann T